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THE LANCET
Mutations in the MEN I gene in 
sporadic neuroendocrine tumours 
of gastroenteropancreatic system
Mohammad-Reza Toliat, Wolfgang Berger, H Hilger Ropers, 
Peter Neuhaus, Bertram Wiedenmann
Neuroendocrine tumours of the gastroenteropancreatic 
(GEP) system occur in sporadic as well as hereditary forms. 
About one tenth of these tumours are associated with a 
familial cancer syndrome—multiple endocrine neoplasia 
(MEN) type I (MEN I). These tumours appear to originate 
embryonically from organs attributable to the foregut. 1 The 
MEN I gene has been identified by positional cloning. This 
gene is localised on chromosome 1 l q l 3 and encodes a 
polypeptide (menin) of 610 aminoacid residues. The 
function of this putative tumour suppressor gene is as 
yet unknown.2 With microsatellite markers around the 
menin-gene region, loss of heterozygosity (LOH) was 
observed in sporadic neuroendocrine GEP tumours. 
However., by contrast with existing clinical data1 LOH was 
not only found in foregut, but also in midgut and hindgut 
tumours.3
We analysed tumour tissue DNA from 43 patients with 
sporadic tumours. Mutation screening by the single strand 
conformation polymorphism (SSC) technique.4 The open 
reading frame of 1830 bp was covered by 15, partly 
overlapping PCR fragments. Primer sequences and PGR 
conditions are available at http://www.mpimg-berlin- 
dahlem-mpg.de/abt_rop/moleculargen/menl .html. Several 
bandshifts were detected in different exons and direct 
sequencing of the respective PCR products revealed six 
mutations in sporadic tumours (table), Patients had 
histologically proven neuroendocrine GEP tumour 
disease.5 Patients with sporadic tumours were stratified in 
four groups, according to the location of the primary 
tumour: 1 foregut (n=23; stomach 3, pancreas 18, 
duodenum 2); 2 midgut (n=13; jejunum 1, ileum 8 , 
caecum 3, appendix 1); 3 hindgut (n=3); 4 unknown 
primary (n=4). Tumour tissues of 18 patients with GEP 
adenocarcinomas (colorectum, 14; pancreas, 3; stomach 1) 
served as negative controls.
In six out of 43 patients with sporadic tumours of the 
foregut, midgut, and hindgut, mutations of the menin gene 
were identified only in foregut tumours. Affected patients 
had (age in years tumour size in cm at first diagnosis): 
solitary benign insulinoma (40/1)., metastatic, pancreatic 
VIPoma (31/6); metastatic (mainly liver) non-functional, 
pancreatic neuroendocrine tumours (43/6, 51/3, and 76/2);
Patient SSCP pattern
Blood Tumours
Exon Type of 
mutation
Sequence 
alteration in 
tumour DNA
Menin defect
1 + / - 5/6 transition, 
splice acceptor site
A5296G
2 na + /— 5 1 bp deletion, 
frameshift
5187delG1 W265...X
3 + + /- 8 7 bp deletion,
5 bp from intron 7, 
2 bp from exon 8
Q61BÚ&171
4 na + /- 2 transition
missense
G2411A1 G42S
5 na — 2 deletion 
3 bp in frame
2641del3 K119del
6 na + /- 10 transition
missense
G7848A1 A541T
NA=not available. *Numbers refer to sequence accession number U93237; +: normal 
allele; mutant allele; in these cases, the mutant as well as the normal allele were 
identified by DNA sequencing.
MEN I gene mutations in six of 43 sporadic neuroendocrine 
gastroenteropancreatic tumours
and non-metastatic, non-functional hepatic neuroendocrine 
tumour (32/14).
Our findings show that in a subset of sporadic 
neuroendocrine tumours, mutations of the MEN I gene can 
be found. This suggests that these tumours are also subject 
to somatic mutation. Consistent with our clinical findings, 
mutations in the MEN I gene appear to be restricted to 
neuroendocrine GEP tumours of the foregut (6/23), 
because no mutations were found in midgut and hindgut 
neuroendocrine tumours nor tumours with unknown 
primary (0/20) nor GEP adenocarcinomas (0/18). Possible 
mechanisms of tumorigenesis include an undetected 
mutation that inactivates the second MEN I allele or its 
expression^ a dominant-negative effect of the mutation, or 
the involvement of additional, so far, unidentified altered 
genes.
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Pseudolymphoma at site of 
clonidine patch
Walter B Shelley, E Dorinda Shelley
An 83-year-old woman consulted us for evaluation of a 
1*0 cm nodule on her right anterior shoulder (figure). It 
was symptomless and had arisen at the site of clonidine 
patches applied during the past year. No lesions were seen 
on her legs where the patches are now being applied. Her 
past history included left hemiplegia, aphasia following a 
right cerebrovascular accident 5 years ago3 and bullous 
pemphigoid. Her blood count was normal.
A skin biopsy specimen showed no changes in the
Nodule on right shoulder
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